Technology

Employing the well-developed and proven plant-made pharmaceutical (PMP) platform, biologics and vaccines can now be easily manufactured and delivered locally, regionally or globally from anywhere. Plants grow quickly and can be encouraged to produce required proteins without the capital expense of traditional big stainless steel bioreactor infrastructure.

Over the last 30 years advancements in using recombinant technologies have been used to produce therapeutic biologic molecules, i.e. antibodies, vaccines, peptides and others. The PMP sector has grown rapidly, in conjunction with the overall biologics revolution, contributing to improvement in human health in developed countries. 

The 2020 pandemic has focused the world on food security and pharmaceutical security and is driving every country around the world to consider ways to manufacture and supply their citizens with needed medicines. PMP and Phylloceuticals’ PhAAST™ platform are keenly aware of this dynamic and have been assisting countries, regions and companies with ways to mitigate their supply chain issues around needed cancer, diabetes and inflammatory disease medicines with their rapid response platform.

Our response to these opportunities is to provide PHarmaceuticals As A Service Technology (PhAAST™) to customers in key geographic regions around the world.